Minghui Pharmaceutical presented complete Phase I/II data for MHB018A, its subcutaneous anti-insulin-like growth factor 1 receptor antibody for active and chronic thyroid eye disease, at ENDO 2026. The data place MHB018A more firmly in a competitive field where established intravenous therapy and emerging subcutaneous challengers are reshaping expectations for efficacy, convenience, safety, and future regulatory positioning.
The strategic significance is not simply that MHB018A produced encouraging response rates. The more important point is that Minghui Pharmaceutical is trying to enter thyroid eye disease at a moment when the treatment conversation has already moved beyond proof that insulin-like growth factor 1 receptor inhibition can work. The market is now asking a harder question: which drug can combine meaningful proptosis reduction, diplopia improvement, manageable hearing-related safety, convenient administration, and broad usefulness across active and chronic disease?
That makes MHB018A an interesting but still unproven contender. The Phase I/II results at the 450 mg every-four-weeks dose suggest clinically relevant activity in two thyroid eye disease populations that matter commercially and scientifically. In active thyroid eye disease, MHB018A showed an 81 percent proptosis response at Week 12, alongside a mean proptosis change of 2.83 mm, a high rate of Clinical Activity Score improvement to 0 or 1, and notable diplopia response. In chronic thyroid eye disease, the same dose showed a 76 percent proptosis response at Week 24, with a mean proptosis change of 2.65 mm and a 50 percent complete resolution rate for diplopia. Those numbers are eye-catching, but the key caveat is equally important: this remains Phase I/II evidence from relatively small patient groups, not the kind of randomized global Phase III proof that changes prescribing behavior on its own.
What the MHB018A results reveal about the new benchmark for IGF-1R therapies
The thyroid eye disease market has become a proving ground for differentiated insulin-like growth factor 1 receptor inhibition. Tepezza, the approved teprotumumab product, validated the mechanism and changed expectations in a disease historically managed with steroids, surgery, watchful waiting, or imperfect supportive care. However, its intravenous administration burden, safety warnings, and real-world access challenges have left room for competitors to argue that the next generation of therapies should be easier to deliver and potentially better tolerated.
That is where MHB018A’s subcutaneous profile matters. A once-every-four-weeks subcutaneous regimen could be commercially meaningful if Phase III trials confirm that the response is durable, reproducible, and safe across broader patient groups. In rare and specialty diseases, convenience is not cosmetic. It can influence referral patterns, treatment initiation, infusion-center dependence, payer discussions, and patient willingness to start therapy before symptoms become long-standing or surgically entrenched. For clinicians, a simpler regimen only becomes attractive if it preserves the clinical depth of intravenous IGF-1R therapy while avoiding new safety trade-offs.
The risk is that convenience alone no longer looks differentiated. The competitive field has moved quickly, with subcutaneous Tepezza development and Viridian Therapeutics’ elegrobart program already pushing the same administration theme. That means MHB018A is not entering a vacuum. It will need to show that its profile is not just easier than legacy intravenous therapy, but strong enough to compete against other convenient IGF-1R options that may reach regulators and clinicians first.
Why active and chronic thyroid eye disease data could widen the commercial opportunity
One of the more meaningful aspects of the MHB018A dataset is the inclusion of both active and chronic thyroid eye disease. Active thyroid eye disease has historically been the cleaner development setting because inflammation, disease activity, and measurable change are more apparent. Chronic thyroid eye disease is commercially important because many patients live with persistent proptosis, diplopia, and quality-of-life impairment long after the inflammatory phase has cooled. A therapy that works credibly in chronic disease could broaden the treatable population and support a larger long-term market.
MHB018A’s chronic thyroid eye disease signal therefore deserves attention. A 76 percent proptosis response at Week 24 and a 50 percent complete resolution rate for diplopia suggest that the drug may have potential beyond early inflammatory disease. If reproduced in larger controlled studies, that could strengthen the case for treating thyroid eye disease as a wider autoimmune and tissue-remodeling disorder rather than a narrow acute inflammatory episode. It could also give clinicians a reason to reconsider patients who might otherwise be sent primarily toward surgical pathways after disease stabilization.
The unresolved question is whether the chronic results will hold up under Phase III conditions. Chronic thyroid eye disease trials can be difficult because baseline inflammation may be lower, placebo effects and measurement variability can complicate interpretation, and patients may have long-standing structural changes that do not reverse easily. Regulators and clinicians will therefore look closely at trial design, baseline severity, activity scores, diplopia definitions, durability after treatment, and whether improvement translates into functional benefit rather than only numerical proptosis response.
How MHB018A compares with Tepezza and emerging subcutaneous competitors
The competitive comparison for MHB018A starts with Tepezza because it remains the reference product in thyroid eye disease. Tepezza established IGF-1R inhibition as a therapeutic category and has clinical experience that newer entrants cannot yet match. Its major advantage is not only efficacy history, but also physician familiarity, regulatory approval, reimbursement pathways, and accumulated real-world use. For any challenger, especially one still moving through Phase III, displacing or even meaningfully sharing that market requires more than an attractive early dataset.
MHB018A’s potential differentiation sits in its subcutaneous every-four-weeks administration and its reported safety profile, particularly around hearing-related adverse events. Hearing impairment has become one of the most watched safety issues for IGF-1R therapies in thyroid eye disease. Minghui Pharmaceutical’s Phase I/II safety summary indicates that all hearing-related adverse events were Grade 1 and that no severe or permanent hearing damage was reported among 98 treated patients. That is clinically relevant because prescribers may become more selective if several drugs deliver broadly similar efficacy, and tolerability could become a major deciding factor.
However, cross-trial comparisons are risky. MHB018A’s active thyroid eye disease data at Week 12 cannot be cleanly compared with Week 24 Phase III outcomes from other programs. Differences in patient eligibility, baseline severity, disease duration, endpoint hierarchy, response definitions, placebo rates, geography, imaging methods, and study conduct can all distort apparent advantages. Industry observers are likely to treat MHB018A as a promising entrant, but not yet as a proven superior product. The bar will be set by controlled Phase III evidence, not headline response rates from earlier studies.
Why safety, hearing effects, and durability may decide more than response rates
The safety narrative around MHB018A could become just as important as the efficacy narrative. IGF-1R inhibition is a validated mechanism, but the class has known concerns that include hearing impairment, metabolic effects such as hyperglycemia, muscle spasms, infusion or administration-related reactions, and potential tolerability issues that may influence completion rates. A new entrant that can demonstrate comparable efficacy with fewer serious or persistent adverse events would have a strong clinical and commercial argument.
For MHB018A, the early safety signal is encouraging but limited. Ninety-eight treated patients provide useful information, particularly when no severe or permanent hearing damage is reported, but this sample is still too small to fully characterize less common risks. Phase III trials will need to show whether the favorable safety profile persists across larger and more diverse patient groups, including older patients, patients with pre-existing hearing issues, patients with diabetes risk, and those with comorbid autoimmune disease. Regulators are unlikely to rely on early tolerability alone when the class already carries safety scrutiny.
Durability is another missing piece. Thyroid eye disease therapies need to deliver more than short-term anatomical improvement. Clinicians will want to understand whether proptosis and diplopia responses persist after the treatment course, whether retreatment is needed, and whether the drug reduces later surgical intervention. Payers may also ask whether a newer therapy changes long-term costs or simply shifts spending from infusion centers to specialty pharmacy and biologic drug acquisition. These questions are not answered by early response rates, however strong they appear.
What Phase III trials must prove before MHB018A can reshape clinical practice
Minghui Pharmaceutical’s next challenge is execution. The biopharmaceutical developer is evaluating MHB018A in ongoing Phase III trials in China, with topline data anticipated in the third quarter of 2026, while global Phase III trials have been initiated with first patient enrollment targeted for the fourth quarter of 2026. This timeline matters because the thyroid eye disease field is moving quickly and competitor positioning may look different by the time MHB018A has registrational data.
The design of the Phase III program will be central to how regulators and clinicians interpret the drug. Randomized, double-blind, placebo-controlled studies in active and chronic thyroid eye disease can provide the evidentiary strength missing from Phase I/II results. Regulators will likely focus on proptosis responder rate, mean proptosis change, diplopia response, Clinical Activity Score improvement in active disease, safety discontinuations, hearing-related adverse events, and consistency across prespecified subgroups. For global adoption, Minghui Pharmaceutical will also need to show that trial populations are relevant to U.S., European, and other international clinical practice settings.
Commercially, the timing creates both opportunity and pressure. If MHB018A produces strong Phase III results, it could enter a market where clinicians are already primed to consider subcutaneous IGF-1R therapy. If competitors secure approvals first, Minghui Pharmaceutical may need sharper differentiation on dosing frequency, administration setting, safety, durability, pricing, or access strategy. In specialty markets, being later is not fatal, but being later without a clear reason to switch is usually expensive.
Why manufacturing, access, and reimbursement could shape MHB018A’s real-world value
Even if MHB018A succeeds clinically, commercial adoption will depend on practical execution. Biologic therapies for rare autoimmune ophthalmic diseases are not simple launches. They require reliable manufacturing, cold-chain logistics, specialist education, patient support infrastructure, payer negotiation, and a clear route for ophthalmologists and endocrinologists to identify eligible patients. A subcutaneous format can reduce some administration burden, but it can also shift complexity toward specialty pharmacy, training, adherence monitoring, and home-use support.
Minghui Pharmaceutical’s global ambitions therefore raise questions beyond the molecule. Can the U.S.-linked and China-based operating structure support rapid multinational trials, regulatory submissions, and eventual commercialization? Will Minghui Pharmaceutical partner in major markets or build commercial capabilities alone? Can it secure reimbursement in a field where Tepezza has already anchored high-cost biologic expectations? These questions will become more pressing if Phase III data are positive because payers may demand evidence that MHB018A is not merely another premium-priced IGF-1R product with a different delivery route.
The adoption curve may also depend on physician segmentation. Oculoplastic surgeons, neuro-ophthalmologists, endocrinologists, and general ophthalmologists may weigh the same dataset differently. Some may prioritize response rates and durability. Others may place heavier weight on hearing-related safety, home administration, or suitability for chronic patients. MHB018A’s value proposition will need to speak to all these audiences without overpromising what early data can support.
What clinicians, regulators, and industry watchers will be watching next
The next major test for MHB018A is whether the Phase I/II profile survives the transition into larger, controlled studies. Clinicians will watch for consistency in proptosis response, meaningful diplopia improvement, and safety across active and chronic thyroid eye disease. Regulators will examine whether the benefit-risk profile is clear enough to support approval in one or both disease settings. Industry watchers will compare the data against approved Tepezza, subcutaneous Tepezza development, Viridian Therapeutics’ elegrobart, and other emerging IGF-1R programs.
The genuine novelty in MHB018A is not the target. IGF-1R is already validated. The potential novelty is the combination of subcutaneous delivery, every-four-weeks dosing, early activity in both active and chronic disease, and a reported low-grade hearing-event profile. That combination could matter if confirmed. But the word “if” is doing serious work here. The thyroid eye disease market is increasingly sophisticated, and early efficacy signals will not be enough to win unless they translate into durable Phase III outcomes and a practical commercial model.
For now, MHB018A should be viewed as a credible late-stage challenger rather than a market disruptor in waiting. Its Phase I/II data give Minghui Pharmaceutical a stronger platform for Phase III development, but they also place the drug under sharper scrutiny. The opportunity is real because thyroid eye disease remains underdiagnosed, undertreated, and burdensome for many patients. The risk is equally real because competitors are advancing quickly, safety expectations are rising, and future differentiation will depend on clean evidence rather than convenience claims alone.
If MHB018A delivers in Phase III, Minghui Pharmaceutical could become a more visible player in autoimmune ophthalmology and join the next wave of companies redefining thyroid eye disease treatment. If the larger trials dilute the early response rates or reveal a more complicated safety profile, the program may still have value, but its competitive room will narrow. That makes the upcoming Phase III readouts more than a routine development milestone. They are the point at which MHB018A’s promise has to become clinically and commercially defensible.
